Liver disease induced by perhexiline maleate.

No abstract is available for this paper.

• Publication year

  1981

• Venue

  Medical Journal of Australia

• Publication date

  1981-11-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.5694/J.1326-5377.1981.TB112984.XPMID 7110022
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-performance liquid chromatographic assay of perhexiline maleate in plasma.

  1981cited by this paper
• Liver disease induced by perhexiline maleate.

  1981cited by this paper
• Liver damage associated with perhexiline maleate.

  1979cited by this paper
• Polyneuropathy with normal metabolism of perhexiline maleate

  1978cited by this paper
• Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy

  1978cited by this paper

• Implication of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase and Its Inhibitors in Alzheimer’s Disease Murine Models

  2021cites this paper
• The 'Goldilocks zone' of fatty acid metabolism; to ensure that the relationship with cardiac function is just right.

  2017cites this paper
• Experimental and early investigational drugs for angina pectoris

  2016cites this paper
• Pharmacological approaches to coronary microvascular dysfunction.

  2014cites this paper
• Efficacy of Metabolic Modulators in Ischemic Heart Disease: An Overview

  2012cites this paper
• Metabolic Modulation: A New Therapeutic Target in Treatment of Heart Failure

  2011cites this paper
• Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial

  2011cites this paper
• Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease

  2010cites this paper
• Multi‐centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope

  2009cites this paper
• Overview of emerging pharmacologic agents for acute heart failure syndromes

  2008cites this paper
• Rationaler Einsatz von Katecholaminen und Inotropika

  2007cites this paper
• Potential of metabolic agents as adjunct therapies in heart failure.

  2007cites this paper
• Review of current and investigational pharmacologic agents for acute heart failure syndromes.

  2007cites this paper
• Metabolic management of diabetic patients with ischaemic heart disease

  2007cites this paper
• Emerging therapies for the management of decompensated heart failure: from bench to bedside.

  2006cites this paper
• merging Therapies for the anagement of Decompensated Heart Failure rom Bench

  2006cites this paper
• Mechanisms of hypertransaminemia

  1996cites this paper
• The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity.

  1995cites this paper
• Cirrhosis of the liver following therapy with perhexiline maleate.

  1983cites this paper
• Perhexiline Maleate Induced Cirrhosis

  1983cites this paper
• Perhexiline and liver cirrhosis.

  1983cites this paper
• Anti-anginal and beta-adrenoceptor blocking drugs

  1981cites this paper
• disease a new therapeutic paradigm in cardiovascular Modification of myocardial substrate utilisation :

  year unknowncites this paper